Keynatinib in Treated Patients with NSCLC and Brain Metastases
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer with EGFR MutationBrain Metastases
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Medolution Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04824079
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Phase Ib Clinical Study of Keynatinib
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Medolution Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT04807881
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath